GALT
NASDAQ · Biotechnology
Galectin Therapeutics Inc
$3.46
+0.32 (+10.19%)
Open$3.15
Previous Close$3.14
Day High$3.49
Day Low$3.04
52W High$7.13
52W Low$2.03
Volume—
Avg Volume199.4K
Market Cap301.04M
P/E Ratio—
EPS$-0.43
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+274.6% upside
Current
$3.46
$3.46
Target
$12.96
$12.96
$9.51
$12.96 avg
$17.52
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 42.71M | 37.98M | 43.70M |
| Net Income | -4,071,906 | -4,331,190 | -4,441,576 |
| Profit Margin | -9.5% | -11.4% | -10.2% |
| EBITDA | -6,278,520 | -5,337,134 | -5,924,921 |
| Free Cash Flow | -4,174,488 | -3,744,064 | -5,531,991 |
| Rev Growth | +12.9% | +2.3% | +21.5% |
| Debt/Equity | 0.88 | 1.10 | 1.06 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |